Street Children’s Rights and the Convention on the Rights of the Child: A study of acceptance and observance in Mexico and Ecuador

This paper offers a first template for assessing performance by national governments in guaranteeing disadvantaged groups of youngsters access to their rights, as enshrined in the Convention on the Rights of the Child (CRC). Street children, who are among the most severely disadvantaged children of any society, are the particular focus of this paper. The 1989 UN Convention on the Rights of the Child (CRC) constitutes a bold new approach to children’s rights, requiring governments to assume new commitments to helping street children. Latin America has a particularly strong history of work with street children, spanning at least 30 years, but governments have not managed to guarantee access by street children to their basic human rights. This paper explores CRC adherence with respect to street children in two Latin American countries – Mexico, a fairly affluent country and Ecuador, a relatively poor one. I divide my exploration of each country’s observance of the CRC into the broad fields of legislation, implementation and enforcement, and assess governmental progress in the decade since their ratification of the Convention. Findings are disappointing for both countries: they suggest that domestic legislation is still inadequate, and that neither government has implemented the policies or allocated the budgetary resources necessary to ensure that street children gain access to their rights. Regrettably, data collection, monitoring of implementation and measurement of outcomes, are all gravely inadequate for enforcement of CRC provisions in Mexico and Ecuador. The findings suggest that strong monitoring and enforcement mechanisms are required to counter existing disincentives for governments to invest in street children. Substantial improvements are needed, particularly in the field of enforcement, before street children in Mexico and Ecuador can gain consistent access to their basic human rights. The prospects for Ecuador’s street children are particularly bleak: the government will need considerable international support to be able to deliver on its commitments to street children under the CRC. Mexico has a more developed political economy and has made more progress than Ecuador; the Mexican government is in a position to make substantial advances toward guaranteeing street children their rights as provided by the CRC.

Square holes for round pegs: "street" children's experiences of social policy processes 2002-2005 in Puebla City, Mexico

A growing body of sociological and anthropological literature recognizes 'street children' as a socially constructed category. Social policy research highlights the dynamic and political nature of policy-to-intervention processes. Children who live on urban streets ostensibly benefit from a range of social interventions, but street children as targets of social policy are under-researched. This thesis explores experiences of 'street' children in their take-up of social Interventions and the policies that lie behind them. Adopting a layered case study approach, focused on Puebla City, Mexico, between 2002 and 2005, I used qualitative research methods (interviews, observation, documentation) to build a rich picture of social policy processes through exploring experiences of 24 street-living children, families, service providers and policy-makers. This thesis argues that government research and policies relating to Puebla City constructed simplistic notions of 'street children' as children whose lives play out on the streets. My findings suggested public spaces occupied a limited part of children's lives while street-living children and their families remained connected, but social interventions proved resistant to reuniting them. Specialist NGO interventions appeared to provide a better 'fit' for street-living children and families than interventions designed for larger populations of vulnerable or deviant children. Unregulated self-help groups were left, unsuccessfully, to bridge the gap of treatment for child substance abuse. My thesis suggests that social policy processes construct and then deconstruct 'street children' to fit available social interventions, disregarding children's experiences and outcomes, forcing street-living children (round pegs) into social interventions designed for other populations (square holes). This distorts higher order policy goals with the stated aim of including children in mainstream society; with the illusory benefit of saving resources in the short term but with further exclusionary effects for street-living children. Recommendations include recognizing children as service end-users, and acknowledging families and service providers as key stakeholders

Pentaquark baryons in SU(3) quark model

We study the SU(3) group structure of pentaquark baryons which are made of four quarks and one antiquark. The pentaquark baryons form {1}, {8}, {10}, {10}-bar, {27}, and {35} multiplets in SU(3) quark model. First, the flavor wave functions of all the pentaquark baryons are constructed in SU(3) quark model and then the flavor SU(3) symmetry relations for the interactions of the pentaquarks with three-quark baryons and pentaquark baryons are obtained.Comment: REVTeX, 36 pages, 8 figures, references added, section for mass sum rules is added, to appear in Phys. Rev.

Phase 2 randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis

Purpose: To evaluate the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK), a rare degenerative corneal disease resulting from impaired corneal innervation. Design: Phase 2 multicenter, randomized, double-masked, vehicle-controlled trial. Participants: Patients with stage 2 (moderate) or stage 3 (severe) NK in 1 eye. Methods: The REPARO phase 2 study assessed safety and efficacy in 156 patients randomized 1:1:1 to rhNGF 10 μg/ml, 20 μg/ml, or vehicle. Treatment was administered 6 drops per day for 8 weeks. Patients then entered a 48- or 56-week follow-up period. Safety was assessed in all patients who received study treatment, whereas efficacy was by intention to treat. Main Outcome Measures: Corneal healing (defined as <0.5-mm maximum diameter of fluorescein staining in the lesion area) was assessed by masked central readers at week 4 (primary efficacy end point) and week 8 (key secondary end point) of controlled treatment. Corneal healing was reassessed post hoc by masked central readers using a more conservative measure (0-mm staining in the lesion area and no other persistent staining). Results: At week 4 (primary end point), 19.6% of vehicle-treated patients achieved corneal healing (<0.5-mm lesion staining) versus 54.9% receiving rhNGF 10 μg/ml (+35.3%; 97.06% confidence interval [CI], 15.88–54.71; P < 0.001) and 58.0% receiving rhNGF 20 μg/ml (+38.4%; 97.06% CI, 18.96–57.83; P < 0.001). At week 8 (key secondary end point), 43.1% of vehicle-treated patients achieved less than 0.5-mm lesion staining versus 74.5% receiving rhNGF 10 μg/ml (+31.4%; 97.06% CI, 11.25–51.49; P = 0.001) and 74.0% receiving rhNGF 20 μg/ml (+30.9%; 97.06% CI, 10.60–51.13; P = 0.002). Post hoc analysis of corneal healing by the more conservative measure (0-mm lesion staining and no other persistent staining) maintained statistically significant differences between rhNGF and vehicle at weeks 4 and 8. More than 96% of patients who healed after controlled rhNGF treatment remained recurrence free during follow-up. Treatment with rhNGF was well tolerated; adverse effects were mostly local, mild, and transient. Conclusions: Topical rhNGF is safe and more effective than vehicle in promoting healing of moderate-to-severe NK

Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis

Neurotrophic keratitis/keratopathy (NK), a rare degenerative corneal disease, lacks effective pharmacologic therapies.1 Because NK pathology involves trigeminal nerve damage and loss of corneal innervation, nerve growth factor (NGF) is surmised to promote healing of NK.2 Preliminary studies with murine NGF demonstrated efficacy for treating corneal neurotrophic ulcers;3 however, the complex tertiary structure of NGF has complicated the production of recombinant human NGF (rhNGF) suitable for clinical development. To this end, we developed an Escherichia coli–derived rhNGF formulation that demonstrated to be well tolerated and safe for topical ophthalmic use in a phase I study in healthy volunteers.4 We report phase I results of topical rhNGF for patients with moderate-to-severe NK

Nanoinformatics: developing new computing applications for nanomedicine

Nanoinformatics has recently emerged to address the need of computing applications at the nano level. In this regard, the authors have participated in various initiatives to identify its concepts, foundations and challenges. While nanomaterials open up the possibility for developing new devices in many industrial and scientific areas, they also offer breakthrough perspectives for the prevention, diagnosis and treatment of diseases. In this paper, we analyze the different aspects of nanoinformatics and suggest five research topics to help catalyze new research and development in the area, particularly focused on nanomedicine. We also encompass the use of informatics to further the biological and clinical applications of basic research in nanoscience and nanotechnology, and the related concept of an extended ?nanotype? to coalesce information related to nanoparticles. We suggest how nanoinformatics could accelerate developments in nanomedicine, similarly to what happened with the Human Genome and other -omics projects, on issues like exchanging modeling and simulation methods and tools, linking toxicity information to clinical and personal databases or developing new approaches for scientific ontologies, among many others

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors

Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates. Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS. Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2 x 10(53)). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2 x 10(-20)). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS. Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management

Search for Branons at LEP

We search, in the context of extra-dimension scenarios, for the possible existence of brane fluctuations, called branons. Events with a single photon or a single Z-boson and missing energy and momentum collected with the L3 detector in e^+ e^- collisions at centre-of-mass energies sqrt{s}=189-209$ GeV are analysed. No excess over the Standard Model expectations is found and a lower limit at 95% confidence level of 103 GeV is derived for the mass of branons, for a scenario with small brane tensions. Alternatively, under the assumption of a light branon, brane tensions below 180 GeV are excluded

Measurement of Exclusive rho^0 rho^0 Production in Two-Photon Collisions at High Q^2 at LEP

Exclusive rho rho production in two-photon collisions involving a single highly virtual photon is studied with data collected at LEP at centre-of-mass energies 89GeV < \sqrt{s} < 209GeV with a total integrated luminosity of 854.7pb^-1 The cross section of the process gamma gamma^* -> rho rho is determined as a function of the photon virtuality, Q^2 and the two-photon centre-of-mass energy, Wgg, in the kinematic region: 1.2GeV^2 < Q^2 < 30GeV^2 and 1.1GeV < Wgg < 3GeV